Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response

Journal of Infectious Diseases

Volumn 205, Issue 4, 2012, Pages 647-655

  Testa, James S ^a   Shetty, Vivekananda ^a   Sinnathamby, Gomathinayagam ^a   Nickens, Zacharie ^a   Hafner, Julie ^a   Kamal, Shivali ^a   Zhang, Xianchao ^b   Jett, Marti ^c   Philip, Ramila ^a  

^a Immunotope Inc   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Walter Reed Army Institute for Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HUMAN; HUMAN CELL; IMMUNOPROTEOMICS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEOMICS; VIRUS STRAIN;

ANTIGENS, VIRAL; CROSS REACTIONS; DENGUE VIRUS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; PROTEOMICS; SEROTYPING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84863056134     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir814     Document Type: Article

References (47)

1. Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 36(Suppl 1):S40-2.
2. World Health Organization. Report of the Scientific Working Group on Dengue. Geneva: WHO, 2006.
3. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004; 113:946-51. (Pubitemid 38544112)
4. Chaturvedi UC, Shrivastava R, Nagar R. Dengue vaccines: problems and prospects. Indian J Med Res 2005; 121:639-52.
5. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu RevMicrobiol 1990; 44:649-88.
6. Heinz FX. Epitope mapping of flavivirus glycoproteins. Adv Virus Res 1986; 31:103-68.
7. Mahoney R, Chocarro L, Southern J, Francis DP, Vose J, Margolis H. Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries. PLoS Med 2011; 8:e1000418.
8. Guirakhoo F, Pugachev K, Arroyo J, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:146-59. (Pubitemid 34734888)
9. Johnson BW, Chambers TV, Crabtree MB, et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 2002; 67:260-5. (Pubitemid 35178349)
10. Kochel T, Wu SJ, Raviprakash K, et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997; 15:547-52. (Pubitemid 27188622)
11. Milich DR. Synthetic T and B cell recognition sites: implications for vaccine development. Adv Immunol 1989; 45:195-282. (Pubitemid 19195508)
12. Barrett AD. Current status of flavivirus vaccines. Ann N Y Acad Sci 2001; 951:262-71. (Pubitemid 34060050)
13. Monath TP,McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18. (Pubitemid 34135935)
14. Raviprakash K, Porter KR, Kochel TJ, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81:1659-67. (Pubitemid 30427070)
15. Steward MW, Howard CR. Synthetic peptides: a next generation of vaccine? Immunol Today 1987; 8:51-8. (Pubitemid 17034660)
16. Arnon R, Horwitz RJ. Synthetic peptides as vaccines. Curr Opin Immunol 1992; 4:449-53.
17. Vazquez S, Guzman MG, Guillen G, et al. Immune response to synthetic peptides of dengue prM protein. Vaccine 2002; 20:1823-30. (Pubitemid 34242839)
18. Roehrig JT, Mathews JH, Risi PA, Brubaker JR, Hunt AR. Mapping of biologically active helper T-cell epitopes on the flavivirus envelope glycoprotein. In: Ginsberg H, Brown F, Lerner RA, Chanock, RM, editors. Vaccines 92. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1992; 227-81.
19. Roehrig JT, Risi PA, Brubaker JR, et al. T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 1994; 198:31-8.
20. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140: 527-33. (Pubitemid 10172725)
21. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146:201-17. (Pubitemid 8139503)
22. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000. (Pubitemid 38373090)
23. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989; 11(Suppl 4):S830-9.
24. Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health 1987; 18:316-20.
25. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997; 142:897-916. (Pubitemid 27218413)
26. Gwinn W, Sun W, Innis BL, Caudill J, King AD. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg 2003; 69:39-47.
27. Rothman AL, Kanesa-thasan N, West K, Janus J, Saluzzo JF, Ennis FA. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 2001; 19:4694-9. (Pubitemid 32800752)
28. Innis BL, Eckels KH, Kraiselburd E, et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1988; 158:876-80.
29. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 2010; 12:157-64.
30. Gagnon SJ,ZengW, Kurane I, Ennis FA. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD41 cytotoxic T-lymphocyte clones. J Virol 1996; 70:141-7. (Pubitemid 126508779)
31. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. Dominant recognition by human CD81 cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 1996; 98:1684-91. (Pubitemid 26327880)
32. Rothman AL, Kurane I, Lai CJ, et al. Dengue virus protein recognition by virus-specific murine CD81 cytotoxic T lymphocytes. J Virol 1993; 67:801-6. (Pubitemid 23032058)
33. Leclerc C, Deriaud E, Megret F, Briand JP, Van Regenmortel MH, Deubel V. Identification of helper T cell epitopes of dengue virus E-protein. Mol Immunol 1993; 30:613-25.
34. Bashyam HS, Green S, Rothman AL. Dengue virus-reactive CD81 T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 2006; 176:2817-24.
35. Appanna R, Huat TL, See LL, Tan PL, Vadivelu J, Devi S. Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vaccine Immunol 2007; 14: 969-77.
36. Shetty V, Sinnathamby G, Nickens Z, et al. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J Proteomics 2011; 74:728-43.
37. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003; 61:403-7.
38. Blaney JE Jr, Nobusawa E, Brehm MA, et al. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 1998; 72:9567-74. (Pubitemid 28520820)
39. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-90.
40. Kurane I, Ennis FA. Cytotoxic T lymphocytes in dengue virus infection. Curr Top Microbiol Immunol 1994; 189:93-108. (Pubitemid 24170550)
41. Pervikov Y. Development of dengue vaccine. Dengue Bull 2000; 24:71-6.
42. Chambers TJ, Weir RC, Grakoui A, et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci USA 1990; 87:8898-902. (Pubitemid 120007616)
43. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005; 79:8004-13. (Pubitemid 40853504)
44. Bartholomeusz AI, Wright PJ. Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5. Arch Virol 1993; 128:111-21.
45. Duangchinda T, Dejnirattisai W, Vasanawathana S, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010; 107:16922-7.
46. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255:1261-3.
47. Masakia H, Fujiic Y, Irimajirib K, Tomuraa TT, Kurane I. Enhancement of MHC class I binding and immunogenic properties of the CTL epitope peptides derived from dengue virus NS3 protein by anchor residue. Dengue Bull 2008; 32:99.